Overall rank by patents
#29,593
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Neuren Pharmaceuticals Limited
USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
9
Total patents granted
6
CPC technology areas
20.3
Avg claims per patent
+25%
5-year filing velocity
The verdict
Neuren holds 9 US patents across 6 technology areas, rank #29,593 of 50,000 tracked assignees.
- #29,593
- of 50,000 US assignees by volume
- Top 49%
- by Innovation Score (35.5/100)
- 20.3
- avg claims per patent
- +25%
- filing velocity, last 5 yrs
Portfolio overview
Neuren Pharmaceuticals Limited has been granted 9 US utility patents between 2015 and 2025, placing Neuren Pharmaceuticals Limited at rank #29,593 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.3 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Neuren Pharmaceuticals Limited is one of the more focused assignees in the PatentsView dataset. By volume, Neuren sits between Nestwave SAS (9 patents, rank #29,589) and Neutron Therapeutics Llc (9 patents, rank #29,597) - the closest US assignees by grant volume. The composite Innovation Score of 35.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 5 grants, compared with 4 in the 2015–2019 window, a +25% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Neuren Pharmaceuticals Limited's 20.3 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Neuren Pharmaceuticals Limited against peers pursuing similar technology classes.
Who files at Neuren's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Nestwave SAS
Nestwave SAS
9 patents
- Nettalk com
NetTALK.com, Inc.
9 patents
- Netclearance Syst…
Netclearance Systems, Inc.
9 patents
- Neuvector
NeuVector, Inc.
9 patents
- Neurolutions
NeuroLutions, Inc.
9 patents
- Neurovision Imagi…
NeuroVision Imaging, Inc.
9 patents
- Neurocentria
Neurocentria, Inc.
9 patents
- Neutron Therapeut…
Neutron Therapeutics LLC
9 patents
- Neuren Pharmaceut… ◀
Neuren Pharmaceuticals Limited
9 patents
What this shows Neuren holds 9 patents at rank #29,593, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Neuren
By rank, the assignees closest to #29,593 in granted patent volume.
- Nestwave SAS #29,589 · 9 patents
- Nettalk.com, Inc. #29,590 · 9 patents
- Netclearance Systems, Inc. #29,591 · 9 patents
- Neuvector, Inc. #29,592 · 9 patents
- Neurolutions, Inc. #29,594 · 9 patents
- Neurovision Imaging, Inc. #29,595 · 9 patents
- Neurocentria, Inc. #29,596 · 9 patents
- Neutron Therapeutics Llc #29,597 · 9 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Neuren's primary technology class.
- The Regents Of The University Of California 1,779 in class
- L'oreal 1,250 in class
- Novartis Ag 988 in class
- The Procter & Gamble Company 985 in class
- The Board Of Regents Of The University Of Texas System 950 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 813 in class
- The Trustees Of The University Of Pennsylvania 768 in class
- Merck Sharp & Dohme Llc 760 in class
Neuren's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
35 Top 49% higher than 51% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 22.2% |
| 2017 | 1 | 11.1% |
| 2018 | 1 | 11.1% |
| 2020 | 1 | 11.1% |
| 2021 | 1 | 11.1% |
| 2022 | 1 | 11.1% |
| 2024 | 1 | 11.1% |
| 2025 | 1 | 11.1% |
Which technologies does Neuren Pharmaceuticals Limited patent most?
Top 6 of 6 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Growing
Frequently Asked Questions
How many patents does Neuren Pharmaceuticals Limited hold?
Neuren Pharmaceuticals Limited holds 9 US granted patents filed between 2015 and 2025, spanning 6 technology areas.
What is Neuren Pharmaceuticals Limited's Innovation Score?
Neuren Pharmaceuticals Limited has an Innovation Score of 35.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Neuren Pharmaceuticals Limited focus on?
Neuren Pharmaceuticals Limited's top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 9 patents. The company has filed patents in 6 CPC subclasses total.
Is Neuren Pharmaceuticals Limited's patent filing rate increasing or decreasing?
Neuren Pharmaceuticals Limited's recent filing velocity is +25% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Neuren Pharmaceuticals Limited's patents?
Neuren Pharmaceuticals Limited's patents average 20.3 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Neuren Pharmaceuticals Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Neuren's 9 grants land it in the top 49% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Neuren ranks #29,593 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.